Literature DB >> 27569996

The pattern of GPI-80 expression is a useful marker for unusual myeloid maturation in peripheral blood.

Y Takeda1, T Kato2, H Ito2, Y Kurota2, A Yamagishi2, T Sakurai2, A Araki1, H Nara1, N Tsuchiya2, H Asao1.   

Abstract

Myeloid-derived suppressor cells (MDSCs) have a wide spectrum of immunosuppressive activity; control of these cells is a new target for improving clinical outcomes in cancer patients. MDSCs originate from unusual differentiation of neutrophils or monocytes induced by inflammatory cytokines, including granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage (GM)-CSF. However, MDSCs are difficult to detect in neutrophil or monocyte populations because they are not uniform cells, resembling both neutrophils and monocytes; thus, they exist in a heterogeneous population. In this study, we investigated GPI-80, a known regulator of Mac-1 (CD11b/CD18) and associated closely with neutrophil maturation, to clarify this unusual differentiation. First, we demonstrated that the mean fluorescence intensity (MFI) of GPI-80 and coefficient of variation (CV) of GPI-80 were increased by treatment with G-CSF and GM-CSF, respectively, using a human promyelocytic leukaemia (HL60) cell differentiation model. To confirm the value of GPI-80 as a marker of unusual differentiation, we measured GPI-80 expression and MDSC functions using peripheral blood cells from metastatic renal cell carcinoma patients. The GPI-80 CV was augmented significantly in the CD16hi neutrophil cell population, and GPI-80 MFI was increased significantly in the CD33hi monocyte cell population. Furthermore, the GPI-80 CV in the CD16hi population was correlated inversely with the proliferative ability of T cells and the GPI-80 MFI of the CD33hi population was correlated with reactive oxygen species production. These results led us to propose that the pattern of GPI-80 expression in these populations is a simple and useful marker for unusual differentiation, which is related to MDSC functions.
© 2016 British Society for Immunology.

Entities:  

Keywords:  GPI-80/VNN2; MDSCs; myeloid cell differentiation; renal cell carcinoma

Mesh:

Substances:

Year:  2016        PMID: 27569996      PMCID: PMC5108066          DOI: 10.1111/cei.12859

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  44 in total

Review 1.  Myeloid-derived suppressor cells in transplantation and cancer.

Authors:  Jordi C Ochando; Shu Hsia Chen
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

Review 2.  The three human monocyte subsets: implications for health and disease.

Authors:  Kok Loon Wong; Wei Hseun Yeap; June Jing Yi Tai; Siew Min Ong; Truong Minh Dang; Siew Cheng Wong
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

3.  Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy.

Authors:  Bethany L Mundy-Bosse; Gregory S Young; Todd Bauer; Elaine Binkley; Mark Bloomston; Matthew A Bill; Tanios Bekaii-Saab; William E Carson; Gregory B Lesinski
Journal:  Cancer Immunol Immunother       Date:  2011-05-21       Impact factor: 6.968

4.  Myeloid-cell differentiation redefined in cancer.

Authors:  Thomas A Wynn
Journal:  Nat Immunol       Date:  2013-03       Impact factor: 25.606

5.  Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties.

Authors:  Sven Brandau; Sokratis Trellakis; Kirsten Bruderek; Dominik Schmaltz; Gabriele Steller; Motaz Elian; Henrik Suttmann; Marcus Schenck; Jürgen Welling; Peter Zabel; Stephan Lang
Journal:  J Leukoc Biol       Date:  2010-11-24       Impact factor: 4.962

Review 6.  Interleukin-6 signaling pathway in targeted therapy for cancer.

Authors:  Yuqi Guo; Feng Xu; TianJian Lu; Zhenfeng Duan; Zhan Zhang
Journal:  Cancer Treat Rev       Date:  2012-05-29       Impact factor: 12.111

Review 7.  Myeloid-derived suppressor cell heterogeneity in human cancers.

Authors:  Samantha Solito; Ilaria Marigo; Laura Pinton; Vera Damuzzo; Susanna Mandruzzato; Vincenzo Bronte
Journal:  Ann N Y Acad Sci       Date:  2014-06       Impact factor: 5.691

8.  Localization of GPI-80, a beta2-integrin-associated glycosylphosphatidyl-inositol anchored protein, on strongly CD14-positive human monocytes.

Authors:  Dai Sendo; Yuji Takeda; Hitoshi Ishikawa; Fujiro Sendo; Yoshihiko Araki
Journal:  Immunobiology       Date:  2003       Impact factor: 3.144

9.  High-dimensional analysis of the murine myeloid cell system.

Authors:  Burkhard Becher; Andreas Schlitzer; Jinmiao Chen; Florian Mair; Hermi R Sumatoh; Karen Wei Weng Teng; Donovan Low; Christiane Ruedl; Paola Riccardi-Castagnoli; Michael Poidinger; Melanie Greter; Florent Ginhoux; Evan W Newell
Journal:  Nat Immunol       Date:  2014-10-12       Impact factor: 25.606

Review 10.  Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.

Authors:  Mohit Trikha; Robert Corringham; Bernard Klein; Jean-François Rossi
Journal:  Clin Cancer Res       Date:  2003-10-15       Impact factor: 12.531

View more
  2 in total

Review 1.  Relationship between Immunological Abnormalities in Rat Models of Diabetes Mellitus and the Amplification Circuits for Diabetes.

Authors:  Yuji Takeda; Tomoko Shimomura; Hironobu Asao; Ichiro Wakabayashi
Journal:  J Diabetes Res       Date:  2017-02-19       Impact factor: 4.011

2.  GPI-80 Augments NF-κB Activation in Tumor Cells.

Authors:  Yuji Takeda; Yuta Kurota; Tomoyuki Kato; Hiromi Ito; Akemi Araki; Hidetoshi Nara; Shinichi Saitoh; Nobuyuki Tanaka; Norihiko Tsuchiya; Hironobu Asao
Journal:  Int J Mol Sci       Date:  2021-11-06       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.